Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD

Inclusion Criteria: * age between 40 and 79 years, * a diagnosis of MASLD, configured by the presence of hepatic steatosis (proven by instrumental and/or histological methods), with at least one of the five cardiometabolic risk factors (CMRFs) as established by the updated multi-society Delphi consensus proposed criteria, * willingness to sign a valid informed consent Exclusion Criteria: * unavailability or inability to express written consent, * chronic liver diseases other than MASLD/overlap ongoing causes (including chronic hepatitis B virus infection, chronic hepatitis C virus infection, autoimmune hepatitis, chronic cholestasis, genetic diseases determining steatosis, and alcohol-related liver disorder assumed in the evidence of a history of alcohol intake greater than 20 g/day or 140 g/week), * administration of liver-damaging (Drug-induced liver Injury) (DILI) / hepatic steatosis inducing drugs (Drug-Induced Fatty Liver Disease) (DIFLD), * hepatoprotective drugs administration, * consumption of hypoglycemic, hypolipidemic, and weight loss agents, as well as any drug known to influence liver function, * neoplasms, * chronic systemic inflammatory diseases, * eating disorders (ED) * other psychiatric disorders potentially invalidating the consent.